Synergic effect of bacterial glycosidases and digestive proteases on mucus degradation and the reduced risk of inflammatory bowel disease-like gut damage in both germ-free and poor hygiene conditions
✍ Scribed by Xiaofa Qin
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 67 KB
- Volume
- 14
- Category
- Article
- ISSN
- 1078-0998
No coin nor oath required. For personal study only.
✦ Synopsis
Our data suggests that combination therapy of infliximab and azathioprine may alter disease type; however, our retrospective data have certain limitations and such a regimen may not be suitable for all patients with CD.
These are the first real-life data using the Montreal or Vienna classification to suggest that disease progression over time may be retarded, and complement the data on a top-down approach to disease management from Belgium. However, such potent downregulators of an evolved natural defense have important repercussions. The benefits of combined therapies have to be balanced and debated against the increased likelihood of cumulative adverse effects, mainly fatal and serious opportunistic infections and malignancies. 4,9 Individualization of therapy taking into consideration preceding disease course is likely to influence the cohort of patients for which combination therapy may be an acceptable risk. 3,10